Home Ultrasound Imaging

Terason Partners with AmCad BioMed

Today Terason, global ultrasound imaging company based in Burlington, Mass., has partnered with AmCad BioMed Corporation to provide its ultrasound imaging technology for AmCad’s innovative Obstructive Sleep Apnea (OSA) solution, AmCAD®-UO.

The partnership addresses a strong market need for more efficient solutions that help physicians evaluate the risk of OSA, a disorder that affects over 425 million people worldwide.

AmCAD-UO, the world’s first FDA-cleared solution for upper airway assessment, uses artificial intelligence (AI) to analyze and reconstruct upper airway ultrasound images acquired from awake patients using Terason’s ultrasound imaging technology. This allows doctors to more quickly evaluate the root cause of sleep apnea and offer assessment for moderate/severe OSA patients.

“We are pleased that our ultrasound imaging technology is being combined with AmCad’s AI and advanced signal processing to change the way physicians assess and diagnose obstructive sleep apnea,” says Dr. Alice Chiang, Terason’s CEO and founder and industry pioneer. “Using the intuitive solution that leverages the superior clarity of Terason’s ultrasound images, physicians can access diagnostic information about their patient’s upper airway in less than an hour – turning a formerly inefficient process into a convenient outpatient procedure.”

The AmCAD-UO solution is receiving early acclaim in the industry, securing its first U.S. use at University Hospitals Cleveland Medical Center, a major not-for-profit medical complex in Cleveland, Ohio.

“We are very optimistic that the deployment of our AmCAD®-UO solution at University Hospitals Cleveland Medical Center will pave the way to broad acceptance in an industry that is looking for a more efficient way to evaluate obstructive sleep apnea,” says Yi -Li Lee, President of AmCad BioMed. “Our unique technology and partnership with Terason open endless possibilities for clinical research, prediction of surgery success, treatment analysis, and follow-ups.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version